Status:

COMPLETED

Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection

Lead Sponsor:

Aesculap AG

Conditions:

Hemostasis

Liver Surgery

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A total of 126 patients planned for an elective liver resection will be enrolled in 9 surgical centres. The prim...

Detailed Description

During liver resection the control of bleeding is a major concern. The liver is predisposed to diffuse bleeding because of its extreme vascularity. Locally applicable agents (haemostats) are in use in...

Eligibility Criteria

Inclusion

  • Inclusion:
  • Age: \> 18 years
  • Gender: male / female
  • Patients with an indication for liver resection (segmental or non-segmental)
  • Willing and able to complete the clinical trial procedures, as described in the protocol
  • Signed written informed consent to participate in this clinical trial
  • Exclusion:
  • Presence or sequelae of coagulation disorder, liver cirrhosis, Klatskin tumor
  • Concurrent participation in another clinical trial with a medical device or medicinal product or with interfering endpoints
  • Concurrent or previous therapy with systemic pharmacologic agents promoting blood clotting including but not limited to tranexamix acid, activated factor VII, and aprotinine
  • Known allergy or hypersensitivity to a component of the investigational treatments Sangustop® or TachoSil®, to riboflavin or to proteins of bovine origin
  • Pregnancy or breast feeding
  • Inability to understand the nature and the extent of the trial and the procedures required
  • Missing signed written informed consent to participate in the study
  • Exclusion criteria to be checked during surgery (liver resection):
  • Resection area estimated by operating surgeon \< 16cm2
  • Infected wound area
  • Persistant major bleeding after primary haemostasis
  • No bleeding after resection

Exclusion

    Key Trial Info

    Start Date :

    January 1 2010

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2011

    Estimated Enrollment :

    128 Patients enrolled

    Trial Details

    Trial ID

    NCT00918619

    Start Date

    January 1 2010

    End Date

    January 1 2011

    Last Update

    May 28 2015

    Active Locations (8)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (8 locations)

    1

    Universitätsklinik für Chirurgie, Medizinische Universität Graz

    Graz, Austria, 8036

    2

    Charité Campus Virchow, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

    Berlin, Germany, 13353

    3

    Krankenhaus Nordwest, Klinik für Allgemein-, Viszeral- und Minimal Invasive Chirurgie

    Frankfurt, Germany, 60488

    4

    Klinikum der J. W. Goethe-Universität, Klinik für Allgemein- und Visceralchirurgie

    Frankfurt am Main, Germany, 60590

    Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection | DecenTrialz